Genentech announces FDA approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia

Genentech, a member of the Roche Group announced the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA) to evaluate the safety and efficacy of intravenous Actemra® (tocilizumab) plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia.

source https://www.pharmatutor.org/pharma-news/2020/genentech-announces-fda-approval-of-clinical-trial-for-actemra-to-treat-hospitalized-patients-with-severe-covid-19-pneumonia